Skip to main contentSkip to navigationSkip to search

Webcast with Curasight

September 9, 2020


Curasight A/S CEO Ulrich Krasilnikoff and CSO Andreas Kjaer presented the company, its operations and future plans, via a webcast together with Biostock. See below for more information.

Link to webcast:

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60



Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.